Shufro Engnrg Labs

Opexa Therapeutics is a biotechnology company that specializes in the development of patient-specific cellular therapies for the treatment of autoimmune diseases, such as multiple sclerosis and diabetes. It offers Tovaxin, which is a vaccine for early relapsing multiple sclerosis. The company also offers an adult stem cell program that enables the production of multipotent cells generated from patients white blood cells and provides means to differentiate these stem cells into other tissue types. Opexa Therapeutics offers solutions that minimize the threat of treatment rejection. It operates clinical advisory boards for multiple sclerosis and diabetes that take care of the supervision of related procedures. The company provides products to target individual s disease progression and modification.

Antagen Pharmaceuticals Inc., based in Canton, Massachusetts, is a pioneering biotechnological company committed to developing innovative solutions for pressing healthcare challenges, including infectious diseases, cancer, and autoimmune disorders. With a mission focused on revolutionizing healthcare through advanced research and technology platforms, Antagen is at the forefront of delivering cutting-edge biomedical services and products. Offering a comprehensive array of biotechnological services, Antagen specializes in therapeutic antibody development, recombinant protein production, and the development of COVID-19 detection kits. Their dedication to quality and innovation has garnered positive testimonials from clients who praise the company's expertise and reliability in the industry. Generated from the website

Paratek Pharmaceuticals, based in Boston, MA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). With a focus on developing innovative treatment options for complex medical issues, Paratek is committed to combatting AMR through responsible antibiotic use, improved surveillance, and research into new antibiotics. Grounded in a mission to save lives, Paratek's FDA-approved tetracycline-class antibiotic, NUZYRA, targets adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company's disciplined team of experts is driven to provide new technologies that can defeat superbugs and contribute to a vibrant marketplace that recognizes the life-saving value of novel antibiotics.Generated from the website